title: [Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].
abstract: We present a 53-year-old man who underwent proximal gastrectomy for gastric gastrointestinal stromal tumor (GIST) in August 2005. Imatinib mesilate (imatinib) 400 mg/day was started in February 2006 for left adrenal metastasis. Tumor size markedly decreased by April 2006, but medication had to be discontinued due to a pruritic rash. A distal pancreatectomy, splenectomy, and left adrenectomy were performed in August for recurrent adrenal metastases. Imatinib 200 mg/day started postoperatively was discontinued immediately due to fever and pruritus. Local recurrence with peritoneal dissemination was found in February 2007. Imatinib 100 mg/day with prednisolone (PDL) 5 mg/day was discontinued in two days due to pruritic dermatitis. Imatinib 200 mg/day with PDL 40 mg/day was restarted in April due to an increase in tumor size. Treatment continued without obvious side effects, and PDL dosage was tapered to 10 mg/day. The tumor was no longer visible on CT in May 2008, and complete response is being maintained as of August 2009.
authors.affiliation: Dept. of Surgery, Aizawa Hospital.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Tsukada
authors.forename: Katsunori
authors.initials: K
authors.lastname: Tauchi
authors.forename: Masato
authors.initials: M
authors.lastname: Nakamura
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Kishimoto
authors.forename: Seijiro
authors.initials: S
authors.lastname: Yoshifuku
authors.forename: Noriaki
authors.initials: N
authors.lastname: Otagiri
authors.forename: Kotaro
authors.initials: K
authors.lastname: Sasahara
mesh_terms: D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage*; D011537:Pruritus / Q000139:chemically induced / Q000517:prevention & control; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011239:Prednisolone